skip to main content

Biosimilar Nocebo — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDermatopharmacologyBiosimilar NoceboSCE Dermatology

A 55-year-old man has widespread plaque psoriasis that has been well-controlled on Adalimumab biosimilar for 2 years. He reads about 'nocebo effect' associated with biosimilar switching. What is the nocebo effect in this context?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Negative expectations about the biosimilar leading to subjective worsening or new symptoms that are psychologically rather than pharmacologically mediated

The nocebo effect in biosimilar switching refers to negative treatment outcomes (subjective worsening, new symptoms, treatment discontinuation) driven by negative patient expectations about the switch rather than genuine pharmacological differences. Studies show that non-medical switching from originator to biosimilar with adequate patient education produces minimal nocebo effect, while poorly communicated switches have higher nocebo-driven discontinuation rates. BAD guidelines and NHS England recommend that biosimilar switching conversations should: explain the rigorous regulatory equivalence process, provide positive framing, address specific patient concerns, and offer regular follow-up for reassurance. The NOR-SWITCH trial demonstrated no difference in efficacy between Infliximab originator and biosimilar.

Reference: BAD 2020 Biologic Guidelines; NHS England Biosimilar